The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Deerfield Management claims that Alcon Research is seeking a discounted takeover of Aurion Biotech while blocking the startup ...

Price-negotiation provisions that are out of step with reality are discouraging funders and Big Pharma partners from ...

The industry remains unwavering in the commitment to to increased clinical trial accessibility and representation.

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

The World Health Organization names antimicrobial resistance as one of the most urgent public health threats, but it remains ...